ATYR PHARMA, INC.


Associated tags: ATyr Pharma, Pharmaceutical industry, SAN, Research, Biology, RNA transfection, Patient, Sarcoidosis, Small RNA, Inflammation, Neuropilin, Safety, Fibrosis, LIFE

Locations: DENMARK, CANADA, ALBERTA, ONTARIO, SWEDEN, TX, SAN DIEGO, CA, US, GORDON, JAPAN

aTyr Pharma Announces LTBP1 as Target of DARS tRNA Synthetase Fragment

Retrieved on: 
Thursday, December 15, 2022
Scripps Research, Drug discovery, SAN, ATyr Pharma, Disease, Molecular medicine, DARS, Transforming growth factor beta, RNA transfection, Fibrosis, Research, Risk, Biology, COVID-19, Pharmaceutical industry, LTBP1

SAN DIEGO, Dec. 15, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced new findings from its tRNA synthetase platform. The target for a naturally occurring fragment of Aspartyl-tRNA Synthetase (DARS) was identified as latent transforming growth factor beta binding protein 1 (LTBP1).

Key Points: 
  • SAN DIEGO, Dec. 15, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced new findings from its tRNA synthetase platform.
  • The target for a naturally occurring fragment of Aspartyl-tRNA Synthetase (DARS) was identified as latent transforming growth factor beta binding protein 1 (LTBP1).
  • The company expects to present additional findings around the interaction between LTBP1 and this fragment of DARS at an upcoming scientific conference.
  • aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets.

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, November 18, 2022
RNA transfection, Research, SAN, Employment, Financial compensation, Biology, ATyr Pharma, Pharmaceutical industry

These stock awards were granted as an inducement material to the new employees entering into employment with aTyr in accordance with Nasdaq Listing Rule 5635(c)(4) and were made pursuant to the aTyr Pharma, Inc. 2022 Inducement Plan.

Key Points: 
  • These stock awards were granted as an inducement material to the new employees entering into employment with aTyr in accordance with Nasdaq Listing Rule 5635(c)(4) and were made pursuant to the aTyr Pharma, Inc. 2022 Inducement Plan.
  • The options are subject to the terms and conditions of the aTyr Pharma, Inc. 2022 Inducement Plan and the terms and conditions of an award agreement covering the grant.
  • aTyr is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform.
  • aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets.

aTyr Pharma Announces Third Quarter 2022 Results and Provides Corporate Update

Retrieved on: 
Thursday, November 10, 2022
SAN, ILD, GLOBE, Review, Private Securities Litigation Reform Act, Forward-looking statement, IND, Intellectual property, Investment, ATyr Pharma, Patent, NRP2, FDA, FC, Food, Inflammation, EST, Research, Biology, Risk, Proteomics, Drug discovery, Interstitial lung disease, Interest, Sarcoidosis, SEC, Goal, AARS, Safety, PST, FGFR4, Neuropilin, Food and Drug Administration, Biomarker, Cancer, D, Degenerative disease, Patient, RNA transfection, Therapy, Systemic scleroderma, COVID-19, Pharmaceutical industry, Fine chemical

SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced third quarter 2022 results and provided a corporate update.

Key Points: 
  • Ended the third quarter 2022 with $79.6 million in cash, restricted cash, cash equivalents and investments.
  • SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced third quarter 2022 results and provided a corporate update.
  • Announced the publication of results of the Phase 1b/2a study of efzofitimod in patients with pulmonary sarcoidosis in the peer-reviewed medical journal CHEST.
  • G&A Expenses: General and administrative expenses were $3.6 million for the third quarter of 2022.

aTyr Pharma to Present at Upcoming Investor Conferences

Retrieved on: 
Thursday, November 10, 2022
SAN, GLOBE, Research, Biology, RNA transfection, ATyr Pharma, Pharmaceutical industry

Details of the presentations appear below:

Key Points: 
  • Details of the presentations appear below:
    In addition to the presentations, company management will be available to participate in one-on-one meetings with investors who are registered attendees of the conferences.
  • Following the events, a replay of the presentations will be available on the aTyr website for at least 90 days.
  • aTyr is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform.
  • aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets.

aTyr Pharma Announces Publication of Positive Data from Phase 1b/2a Clinical Study of Efzofitimod for the Treatment of Pulmonary Sarcoidosis in the Journal CHEST

Retrieved on: 
Wednesday, November 9, 2022
Quality of life, SAN, GLOBE, Private Securities Litigation Reform Act, Fibrosis, Scar, Forward-looking statement, Manuscript, ATyr Pharma, NRP2, FDA, FC, Inflammation, Research, Biology, Risk, Cough, Department, Granuloma, Death, Interstitial lung disease, Sarcoidosis, Fatigue, SEC, Prognosis, Pulmonology, Fast Track, Safety, Neuropilin, Biomarker, Disease, Degenerative disease, Clinical trial, Cleveland Clinic, Patient, RNA transfection, COVID-19, Medical imaging, Pharmaceutical industry, Dietary supplement

SAN DIEGO, Nov. 09, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the publication in the journal CHEST of positive results from a Phase 1b/2a randomized, double-blind, placebo-controlled clinical trial of its lead therapeutic candidate, efzofitimod, in patients with pulmonary sarcoidosis, a major form of interstitial lung disease. The publication, entitled, “Efzofitimod for the treatment of pulmonary sarcoidosis,” is available on the journal’s website and at: https://doi.org/10.1016/j.chest.2022.10.037.

Key Points: 
  • The publication, entitled, Efzofitimod for the treatment of pulmonary sarcoidosis, is available on the journals website and at: https://doi.org/10.1016/j.chest.2022.10.037 .
  • The ongoing EFZO-FIT study presents the opportunity to evaluate the steroid sparing effects of efzofitimod in a broader clinical trial.
  • The publication of this manuscript marks the first peer-reviewed publication of clinical data for efzofitimod in a major medical journal.
  • The Phase 1b/2a study was a randomized, double-blind, placebo-controlled, multiple-ascending dose clinical trial in 37 patients with pulmonary sarcoidosis.

aTyr Pharma to Webcast Conference Call Reporting Third Quarter 2022 Financial Results

Retrieved on: 
Thursday, November 3, 2022
Biology, GLOBE, RNA transfection, Telephone, Research, Conference, SAN, ATyr Pharma, PIN, Pharmaceutical industry

SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase biology platform, today announced that it will report third quarter 2022 financial results and provide a corporate update after the market close on Thursday, November 10, 2022.

Key Points: 
  • SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase biology platform, today announced that it will report third quarter 2022 financial results and provide a corporate update after the market close on Thursday, November 10, 2022.
  • Management will host a conference call and webcast to review the results and provide an operational update.
  • Participants may join the live webcast by accessing it at the above webcast registration link on the aTyr Events page.
  • aTyr is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase biology platform.

aTyr Pharma to Present at the Jefferies London Healthcare Conference

Retrieved on: 
Tuesday, October 25, 2022
SAN, ATyr Pharma, GLOBE, Biology, Research, Conference, LIFE, RNA transfection, Pharmaceutical industry

Details of the presentation appear below:

Key Points: 
  • Details of the presentation appear below:
    In addition to the presentation, company management will be available to participate in one-on-one meetings with investors who are registered attendees of the conference.
  • An audio webcast of the event will be available on the Investors section of the companys website at www.atyrpharma.com .
  • Following the event, a replay of the presentation will be available on the aTyr website for at least 90 days.
  • aTyr is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform.

aTyr Pharma Announces Research Collaboration with Dualsystems Biotech AG to Identify 10 New Therapeutic Targets

Retrieved on: 
Tuesday, October 11, 2022
SAN, Proteomics, Therapy, SEC, Risk, Biotechnology, Biology, Research, RNA transfection, Private Securities Litigation Reform Act, Drug discovery, IP, FGFR4, AARS, ATyr Pharma, GLOBE, Intellectual property, Forward-looking statement, COVID-19, LIFE, Fine chemical, Pharmaceutical industry

We look forward to discoveries from this collaboration as a way to potentially accelerate drug discovery efforts and identify new drugs from our platform.

Key Points: 
  • We look forward to discoveries from this collaboration as a way to potentially accelerate drug discovery efforts and identify new drugs from our platform.
  • aTyr intends to interrogate the interaction between this fragment of AARS and FGFR4 to determine potential therapeutic indications.
  • aTyr is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform.
  • Dualsystems Biotech is a privately held biotechnology company established in 2006 as a spin-off from the University Zurich, Switzerland.

aTyr Pharma to Participate in RBC Biotech Expert Insights: Pulmonary/Lung Disease Mini-Symposium

Retrieved on: 
Tuesday, October 4, 2022
Degenerative disease, Biology, ATyr Pharma, Research, KOL, Scleroderma, Sarcoidosis, Systemic scleroderma, RNA transfection, SAN, LIFE, RBC, GLOBE, Pharmaceutical industry

Details of the presentation appear below:

Key Points: 
  • Details of the presentation appear below:
    The Mini-Symposium will include a series of company presentations and Key Opinion Leader (KOL) sessions in the area of pulmonary/lung disease.
  • Planned KOL interviews include physician experts in pulmonary sarcoidosis and systemic sclerosis (SSc, also known as scleroderma)-associated interstitial lung disease, among other disease indications.
  • To attend the KOL sessions, investors may contact their RBC sales representative to register.
  • aTyr is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform.

aTyr Pharma Announces Notice of Allowance for U.S. Patent for Anti-Neuropilin-2 (NRP2) Monoclonal Antibodies

Retrieved on: 
Thursday, September 29, 2022
Therapy, Inflammation, RNA transfection, LIFE, COVID-19, Risk, IND, Antibody, Chemokine, Semaphorin, Private Securities Litigation Reform Act, VEGF, Forward-looking statement, Program, ATyr Pharma, Cancer, USPTO, Biology, Goal, Patent, Method, SAN, Research, GLOBE, SEC, NRP2, Generic drug, Pharmaceutical industry

16/376,979 titled, Compositions and methods comprising anti-NRP2 antibodies, covers the use of a series of antibodies targeting NRP2 for differentiated therapeutic applications in the areas of cancer and inflammation.

Key Points: 
  • 16/376,979 titled, Compositions and methods comprising anti-NRP2 antibodies, covers the use of a series of antibodies targeting NRP2 for differentiated therapeutic applications in the areas of cancer and inflammation.
  • The blocking antibodies that aTyr has developed target distinct domains of NRP2, including those interacting with semaphorins, VEGF and certain chemokines.
  • A Notice of Allowance is issued after the USPTO makes the determination that a patent should be granted from an application.
  • aTyr is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform.